GlassScriptPhysician profile
Elizabeth Cercone
NPI 1821335993
$5,846.57
in general payments reported to CMS, 2019-2025
46 companies · $552 in 2025
The $552 reported for 2025 was more than what 76% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,676 · 2022: $1,723 · 2023: $1,011 · 2024: $884 · 2025: $552.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,353 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,352.82 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $717.05 | 2021-2025 | Repatha, Otezla, Evenity |
| Abbvie INC. | $633.37 | 2021-2024 | |
| Glaxosmithkline, LLC. | $555.41 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astellas Pharma US INC | $443.31 | 2021-2025 | Veozah, Myrbetriq |
| Lilly USA, LLC | $414.44 | 2021-2025 | Zepbound, Jardiance, Mounjaro |
| Novo Nordisk INC | $375.37 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $319.29 | 2021-2025 | Airsupra, Breztri |
| Baxter Healthcare | $265.06 | 2022 | |
| Esperion Therapeutics, INC. | $231.78 | 2021-2025 | Nexletol, Nexlizet |
| Biohaven Pharmaceutical Holding Company LTD. | $179.07 | 2022 | |
| Dexcom, INC. | $161.51 | 2021-2024 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $146.56 | 2021-2023 | Rexulti |
| Sanofi-Aventis U.S. LLC | $107.32 | 2021-2022 | |
| Pfizer INC. | $92.08 | 2021-2025 | |
| Boston Scientific Corporation | $77.78 | 2025 | Watchman Flx |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Cercone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.